DRUGapproved
Pemigatinib
Mechanism
For FGFR2 fusion/rearrangement iCCA only.
Related claims (50)
| Type | Predicate | Conf | Source |
|---|---|---|---|
| drug efficacy | (clinical trial result) Pemigatinib received Health Canada approval for previously treated locally advanced/metastatic cholangiocarcinoma (CCA) with <i>FGFR2</i> rearrangements/fusions in September 2021. | 100% | 40710216 |
| drug target | Pemigatinib received Health Canada approval for previously treated locally advanced/metastatic cholangiocarcinoma (CCA) with <i>FGFR2</i> rearrangements/fusions. | 100% | 40710216 |
| drug efficacy | Pemigatinib has been approved in Korea for BTC patients with FGFR2 fusions. | 100% | 40033637 |
| drug efficacy | (clinical trial result) Nearly half of patients with pretreated, advanced CCA harbouring an FGFR2 fusion or rearrangement who received pemigatinib had stable disease. | 100% | 38206555 |
| drug efficacy | Pemigatinib is approved for treating cholangiocarcinoma with FGFR2 fusion/rearrangement (clinical trial result). | 100% | 39583123 |
| survival | (clinical trial result) Median progression-free survival in patients with pretreated, advanced CCA harbouring an FGFR2 fusion or rearrangement who received pemigatinib was 7.0 months. | 100% | 38206555 |
| drug efficacy | (clinical trial result) Just over a third of patients with pretreated, advanced CCA harbouring an FGFR2 fusion or rearrangement who received pemigatinib had an objective response. | 100% | 38206555 |
| drug efficacy | Pemigatinib has been approved in Korea for BTC patients with FGFR2 fusions. | 100% | 40033637 |
| drug efficacy | Pemigatinib is an FDA-approved targeted therapy for patients with cholangiocarcinoma (clinical trial result). | 100% | 41226789 |
| drug target | Pemigatinib received Health Canada approval for previously treated locally advanced/metastatic cholangiocarcinoma (CCA) with <i>FGFR2</i> rearrangements/fusions. | 100% | 40710216 |
| drug efficacy | VPS33A knockdown increased cellular sensitivity to Pemigatinib (demonstrated in vitro). | 100% | 41718964 |
| drug efficacy | (observed in patient cohort) The physician-assessed disease control rate was 89% with pemigatinib use in this Canadian PSP cohort. | 100% | 40710216 |
| drug efficacy | (observed in patient cohort) The physician-assessed objective response rate was 56% with pemigatinib use in this Canadian PSP cohort. | 100% | 40710216 |
| drug efficacy | Pemigatinib is approved for patients with cholangiocarcinoma harboring FGFR2 fusions and/or rearrangements (clinical trial result). | 100% | 38424198 |
| drug efficacy | Infigratinib and Pemigatinib are approved for use in cholangiocarcinoma patients with FGFR2 fusions (clinical trial result). | 100% | 38653586 |
| drug efficacy | (observed in patient cohort) The physician-assessed disease control rate was 89% with pemigatinib use in this Canadian PSP cohort. | 100% | 40710216 |
| drug efficacy | (observed in patient cohort) A PFS comparable to that in the phase 2 FIGHT-202 trial was reported with pemigatinib use in this Canadian PSP cohort. | 100% | 40710216 |
| drug efficacy | Infigratinib and Pemigatinib are approved for use in cholangiocarcinoma patients with FGFR2 fusions (clinical trial result). | 100% | 38653586 |
| drug efficacy | Pemigatinib is approved for treating cholangiocarcinoma with FGFR2 fusion/rearrangement (clinical trial result). | 100% | 39583123 |
| drug efficacy | (observed in patient cohort) The physician-assessed objective response rate was 56% with pemigatinib use in this Canadian PSP cohort. | 100% | 40710216 |
| drug efficacy | Pemigatinib is approved for treating cholangiocarcinoma with FGFR2 fusion/rearrangement (clinical trial result). | 100% | 39583123 |
| drug efficacy | Pemigatinib is an approved targeted therapy for CCA (clinical trial result) | 100% | 41226789 |
| drug efficacy | (observed in patient cohort) A PFS comparable to that in the phase 2 FIGHT-202 trial was reported with pemigatinib use in this Canadian PSP cohort. | 100% | 40710216 |
| drug target | Pemigatinib received Health Canada approval for previously treated locally advanced/metastatic cholangiocarcinoma (CCA) with <i>FGFR2</i> rearrangements/fusions. | 100% | 40710216 |
| drug efficacy | (observed in patient cohort) The physician-assessed disease control rate was 89% with pemigatinib use in this Canadian PSP cohort. | 100% | 40710216 |
| drug efficacy | Pemigatinib is approved for treating cholangiocarcinoma with FGFR2 fusion/rearrangement (clinical trial result). | 100% | 39583123 |
| drug target | Pemigatinib received Health Canada approval for previously treated locally advanced/metastatic cholangiocarcinoma (CCA) with <i>FGFR2</i> rearrangements/fusions. | 100% | 40710216 |
| drug efficacy | Infigratinib and Pemigatinib are approved for use in cholangiocarcinoma patients with FGFR2 fusions (clinical trial result). | 100% | 38653586 |
| drug efficacy | (observed in patient cohort) The physician-assessed disease control rate was 89% with pemigatinib use in this Canadian PSP cohort. | 100% | 40710216 |
| drug efficacy | Pemigatinib is approved for treating cholangiocarcinoma with FGFR2 fusion/rearrangement (clinical trial result). | 100% | 39583123 |
| drug efficacy | (clinical trial result) Pemigatinib received Health Canada approval for previously treated locally advanced/metastatic cholangiocarcinoma (CCA) with <i>FGFR2</i> rearrangements/fusions in September 2021. | 100% | 40710216 |
| drug target | Pemigatinib is an inhibitor of fibroblast growth factor receptor (FGFR) 1-3. | 100% | 38206555 |
| drug efficacy | (observed in patient cohort) A PFS comparable to that in the phase 2 FIGHT-202 trial was reported with pemigatinib use in this Canadian PSP cohort. | 100% | 40710216 |
| drug target | Pemigatinib received Health Canada approval for previously treated locally advanced/metastatic cholangiocarcinoma (CCA) with <i>FGFR2</i> rearrangements/fusions. | 100% | 40710216 |
| drug efficacy | (observed in patient cohort) The physician-assessed objective response rate was 56% with pemigatinib use in this Canadian PSP cohort. | 100% | 40710216 |
| drug efficacy | (clinical trial result) Pemigatinib received Health Canada approval for previously treated locally advanced/metastatic cholangiocarcinoma (CCA) with <i>FGFR2</i> rearrangements/fusions in September 2021. | 100% | 40710216 |
| drug efficacy | Pemigatinib is approved for treating cholangiocarcinoma with FGFR2 fusion/rearrangement (clinical trial result). | 100% | 39583123 |
| drug efficacy | Pemigatinib is approved for treating cholangiocarcinoma with FGFR2 fusion/rearrangement (clinical trial result). | 100% | 39583123 |
| drug efficacy | (clinical trial result) Pemigatinib received Health Canada approval for previously treated locally advanced/metastatic cholangiocarcinoma (CCA) with <i>FGFR2</i> rearrangements/fusions in September 2021. | 100% | 40710216 |
| drug target | Pemigatinib received Health Canada approval for previously treated locally advanced/metastatic cholangiocarcinoma (CCA) with <i>FGFR2</i> rearrangements/fusions. | 100% | 40710216 |
| drug target | Pemigatinib received Health Canada approval for previously treated locally advanced/metastatic cholangiocarcinoma (CCA) with <i>FGFR2</i> rearrangements/fusions. | 100% | 40710216 |
| drug efficacy | (observed in patient cohort) The physician-assessed objective response rate was 56% with pemigatinib use in this Canadian PSP cohort. | 100% | 40710216 |
| drug efficacy | (observed in patient cohort) The physician-assessed objective response rate was 56% with pemigatinib use in this Canadian PSP cohort. | 100% | 40710216 |
| drug efficacy | Pemigatinib is approved for treating cholangiocarcinoma with FGFR2 fusion/rearrangement (clinical trial result). | 100% | 39583123 |
| drug efficacy | (clinical trial result) Pemigatinib received Health Canada approval for previously treated locally advanced/metastatic cholangiocarcinoma (CCA) with <i>FGFR2</i> rearrangements/fusions in September 2021. | 100% | 40710216 |
| drug efficacy | Pemigatinib has been approved in Korea for BTC patients with FGFR2 fusions. | 100% | 40033637 |
| drug efficacy | (observed in patient cohort) The physician-assessed disease control rate was 89% with pemigatinib use in this Canadian PSP cohort. | 100% | 40710216 |
| gene expression | Pemigatinib-resistant RBE-R and HuCCT1-R cell lines exhibited elevated VPS33A expression (demonstrated in vitro). | 100% | 41718964 |
| drug efficacy | Pemigatinib is approved for treating cholangiocarcinoma with FGFR2 fusion/rearrangement (clinical trial result). | 100% | 39583123 |
| drug efficacy | Pemigatinib-resistant RBE-R and HuCCT1-R cell lines exhibited autophagy-dependent drug resistance (demonstrated in vitro). | 100% | 41718964 |
Off-Target Findings (0)
No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.